Literature DB >> 22886454

miR-203 inhibits proliferation of HCC cells by targeting survivin.

Wang Wei1, Liu Wanjun, Sun Hui, Chen Dongyue, Yao Xinjun, Zhao Jisheng.   

Abstract

To validate whether down-regulation of microRNA-203 (miR-203) in hepatocellular carcinoma (HCC) is involved in HCC progression by targeting survivin. MiR-203 mimics was transfected into HepG2 cells to enhance miR-203 expression, and miR-203 inhibitor was transfected into HepG2 cells to inhibit miR-203 expression. The effect of up-regulation and down-regulation of miR-203 on survivin expression of HepG2 cells was evaluated using Western blot assay. The effect of miR-203 or survivin expression on the proliferation of HepG2 cells was detected using the CKK-8 assay. Over-expression of miR-203 significantly inhibited the expression of survivin in HepG2 cells (p < 0·05), and down-expression of miR-203 significantly promoted the expression of survivin in HepG2 cells (p < 0·05). Both over-expression of miR-203 and down-regulation of survivin suppressed proliferation of HepG2 cells significantly compared with negative control. Low expression of miR-203 contributes to the progression of HCC via targeting survivin.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22886454     DOI: 10.1002/cbf.2863

Source DB:  PubMed          Journal:  Cell Biochem Funct        ISSN: 0263-6484            Impact factor:   3.685


  33 in total

1.  Function and clinical potential of microRNAs in hepatocellular carcinoma.

Authors:  Lijuan Wang; Yongfang Yue; Xian Wang; Hongchuan Jin
Journal:  Oncol Lett       Date:  2015-09-29       Impact factor: 2.967

2.  Effect of microRNA-203 on tumor growth in human hypopharyngeal squamous cell carcinoma.

Authors:  Ru Wang; Jugao Fang; Hongzhi Ma; Lin Feng; Meng Lian; Fan Yang; Haizhou Wang; Qi Wang; Xiaohong Chen
Journal:  Mol Cell Biochem       Date:  2015-04-04       Impact factor: 3.396

3.  MicroRNA-203 impacts on the growth, aggressiveness and prognosis of hepatocellular carcinoma by targeting MAT2A and MAT2B genes.

Authors:  Maria M Simile; Graziella Peitta; Maria L Tomasi; Stefania Brozzetti; Claudio F Feo; Alberto Porcu; Antonio Cigliano; Diego F Calvisi; Francesco Feo; Rosa M Pascale
Journal:  Oncotarget       Date:  2019-04-19

Review 4.  MicroRNA regulation and therapeutic targeting of survivin in cancer.

Authors:  Jingcao Huang; Hui Lyu; Jianxiang Wang; Bolin Liu
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

5.  Upregulation of UGT2B4 Expression by 3'-Phosphoadenosine-5'-Phosphosulfate Synthase Knockdown: Implications for Coordinated Control of Bile Acid Conjugation.

Authors:  Kathleen G Barrett; Hailin Fang; Daniela Cukovic; Alan A Dombkowski; Thomas A Kocarek; Melissa Runge-Morris
Journal:  Drug Metab Dispos       Date:  2015-05-06       Impact factor: 3.922

6.  Potential roles of EZH2, Bmi-1 and miR-203 in cell proliferation and invasion in hepatocellular carcinoma cell line Hep3B.

Authors:  Fang Yang; Li-Zhi Lv; Qiu-Cheng Cai; Yi Jiang
Journal:  World J Gastroenterol       Date:  2015-12-21       Impact factor: 5.742

Review 7.  MicroRNAs dysregulation in hepatocellular carcinoma: Insights in genomic medicine.

Authors:  Iván Lyra-González; Laura E Flores-Fong; Ignacio González-García; David Medina-Preciado; Juan Armendáriz-Borunda
Journal:  World J Hepatol       Date:  2015-06-18

8.  miR-203 suppression in gastric carcinoma promotes Slug-mediated cancer metastasis.

Authors:  Yan Shi; Yong-Jia Tan; Dong-Zhu Zeng; Feng Qian; Pei-Wu Yu
Journal:  Tumour Biol       Date:  2015-07-21

9.  MiR-203 promotes the growth and migration of ovarian cancer cells by enhancing glycolytic pathway.

Authors:  Zhao Xiaohong; Fan Lichun; Xie Na; Zou Kejian; Xiao Xiaolan; Wang Shaosheng
Journal:  Tumour Biol       Date:  2016-09-21

10.  miR-203 is a predictive biomarker for colorectal cancer and its expression is associated with BIRC5.

Authors:  Qiang Fu; Jun Zhang; Xin Xu; Fei Qian; Ke Feng; Jie Ma
Journal:  Tumour Biol       Date:  2016-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.